Syngenis Labs, a Perth-based biotech company, has successfully raised $4 million in oversubscribed pre-float capital to expedite the development of its comprehensive platform for RNA and DNA-based medicines. The company aims to transform the genetic medicine landscape in Australia, addressing the gap in commercializing research without outsourcing. Its strategy includes building a Good Manufacturing Practice (GMP) facility and leveraging its proprietary AI platform, “Discovery AI,” to streamline drug development. Positioned to capitalize on the global demand for RNA therapeutics, Syngenis plans to integrate multiple revenue streams, avoiding reliance on a single drug candidate, and enhance its role in the evolving biotech sector.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.smh.com.au/business/companies/syngenis-banks-4m-pre-float-to-power-ai-driven-biotech-platform-20260713-p60et3.html
